GENTICEL has selected the prevention of cervical cancer as the medical target to demonstrate the safety and efficacy of its unique therapeutic vaccine platform, the Adenylate Cyclase (CyaA)
The strategic goal of the company is to ensure that a vaccine solution can be offered to all women in order to prevent cervical cancers.
Preventive HPV vaccines are indicated for individuals, mainly teenage girls and young women, who have not yet been exposed to oncogenic Human Papillomavirus (HPV). However, these prophylactics are not effective once one is already infected (Hildesheim et al., 2007; Hung et al., 2008) and because at any given time, approximately 13% of sexually active women bear HPV (De Sanjosé et. al., 2007), Genticel is developing products that are part of a new class of vaccines, ‘therapeutic vaccines’, which remain active after infection and therefore complement the current preventive vaccines.
For more information go to our web page “THE HUMAN PAPILLOMAVIRUS (HPV)”
The strategic goal of the company is to ensure that a vaccine solution can be offered to all women in order to prevent cervical cancers.
Preventive HPV vaccines are indicated for individuals, mainly teenage girls and young women, who have not yet been exposed to oncogenic Human Papillomavirus (HPV). However, these prophylactics are not effective once one is already infected (Hildesheim et al., 2007; Hung et al., 2008) and because at any given time, approximately 13% of sexually active women bear HPV (De Sanjosé et. al., 2007), Genticel is developing products that are part of a new class of vaccines, ‘therapeutic vaccines’, which remain active after infection and therefore complement the current preventive vaccines.
For more information go to our web page “THE HUMAN PAPILLOMAVIRUS (HPV)”
Since February 26, 2010 BT Pharma is now GENTICEL, a biopharmaceutical company that develops therapeutic vaccines.